Coulter Partners places key Chief Scientific Officer at ExpressionEdits

ExpressionEdits is a biotechnology company leveraging AI-driven insights and proprietary intronization technology to enhance protein expression.

Dr. Basran is a seasoned drug discovery leader with over 20 years of experience, specializing in biologic therapies and antibody mimetics. He has held key scientific leadership roles at companies like Avacta, Turbine.AI, and GSK, driving programs from early research to clinical development, including the application of AI and novel drug delivery strategies. His expertise covers a wide range of therapeutic areas, particularly oncology and inflammatory diseases.

As CSO, Dr. Basran will lead the translation of ExpressionEdits’ intronization technology into a pipeline of innovative therapeutics, starting with recombinant protein therapeutics. His focus will be on advancing the company’s internal programs from early research through clinical translation, ensuring that its cutting-edge gene optimization platform directly drives the development of next-generation biologic medicines.

"Amrik’s extensive experience in biologics development makes him an invaluable addition to ExpressionEdits," said Dr. Kärt Tomberg, CEO and Co-Founder of ExpressionEdits. "His leadership will be key as we expand from platform innovation to therapeutic development, ensuring our technology delivers real impact for patients."

Reflecting on the collaboration with Coulter Partners, Dr. Tomberg added: " We greatly valued Coulter Partners' extensive network and industry experience. They presented us with a diverse pool of talent, which enabled us to select Amrik, the ideal Chief Scientific Officer for this stage of our company.”

----

Dr. Amrik Basran, Chief Scientific Officer of ExpressionEdits

Dr. Basran brings over two decades of experience in biologic drug discovery and development, spanning early-stage research to clinical application. He previously served as Chief Scientific Officer at Avacta Life Sciences, where he led the development of an antibody mimetic scaffold, driving programs from discovery through to large scale manufacturing. He also held the CSO role at Curadh MTR and was Chief Discovery Officer at Turbine.AI, applying AI-driven approaches to drug discovery.

Earlier in his career, he held senior scientific roles at Domantis and GlaxoSmithKline (GSK), where he was instrumental in the development of domain antibodies and other protein-based therapeutics. His expertise spans biological scaffolds, antibody mimetics, and targeted protein therapies, with experience in half-life extension strategies, targeted radiopharmaceuticals, and novel drug delivery approaches across oncology and inflammatory diseases.

About ExpressionEdits

About Coulter Partners